Arcadia Biosciences
RKDA
24 hedge funds and large institutions have $1.73M invested in Arcadia Biosciences in 2022 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 7 increasing their positions, 5 reducing their positions, and 4 closing their positions.
50% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 4
40% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 5
9% more funds holding
Funds holding: 22 → 24 (+2)
1% more capital invested
Capital invested by funds: $1.71M → $1.73M (+$23.9K)
0.14% more ownership
Funds ownership: 0.19% → 0.33% (+0.14%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$1.37M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$25.1K |
| 3 |
TSS
Two Sigma Securities
New York
|
+$19.8K |
| 4 |
Jane Street
New York
|
+$18.6K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$13.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$48.7K |
| 2 |
MA
MYDA Advisors
Woodmere,
New York
|
-$40K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$33.9K |
| 4 |
SG
StoneX Group
New York
|
-$13.1K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
-$4.54K |
RKDA Hedge Fund Activity: Q3 2022 in Review
24 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Arcadia Biosciences (RKDA) for Q3 2022, worth a combined $1.73M — up 1.4% from $1.71M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new RKDA positions and 4 closed out — a net gain of 2 holders — while 7 added to existing stakes and 5 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $1.37M. The largest seller was Citadel Advisors, exiting entirely with an estimated $48.7K sold.
- 24 institutional investors held Arcadia Biosciences (RKDA) as of Q3 2022, up from 22 in Q2 2022.
- Funds reported $1.73M of Arcadia Biosciences stock for Q3 2022, up 1.4% quarter-over-quarter.
- 6 funds opened new Arcadia Biosciences positions in Q3 2022 and 4 closed out, a net change of +2 holders.
- The largest Arcadia Biosciences buyer in Q3 2022 was Armistice Capital, an estimated $1.37M added.
- The largest Arcadia Biosciences seller in Q3 2022 was Citadel Advisors, an estimated $48.7K sold.
Based on aggregated 13F filings for Q3 2022.